; promoting ethical research that benefits all individuals, including traditionally underrepresented populations; and protecting research participants. (c) GAO study on barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials (1) In general Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall— (A) complete a study that— (i) reviews what actions Federal agencies have taken to help to address barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials, and identifies challenges, if any, in implementing such actions; and (ii) identifies additional actions that can be taken by Federal agencies to address barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials